<DOC>
	<DOCNO>NCT02769091</DOCNO>
	<brief_summary>The purpose study assess effect TEV-45478 , compare placebo , liver health liver fat content patient T2DM also Nonalcoholic Steatohepatitis ( NASH ) .</brief_summary>
	<brief_title>A Study Adult Patients With Nonalcoholic Steatohepatitis Who Also Have Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<criteria>The patient female male age 18 65 year , inclusive history Type 2 Diabetes Mellitus ( T2DM ) stable medication diabetes insulin combination thereof least 3 month prior screen . The patient NASH Activity Score ( NAS ) â‰¥4 , without evidence fibrosis , score least 1 steatosis lobular inflammation subcomponents NAS hepatocyte ballooning score least 1 score base historical histological evaluation liver biopsy within 12 month prior randomization . The patient historical diagnosis NASH , establish 12 month prior randomization base histology ( liver biopsy ) . The patient ALT level screen 45 105 IU/L , inclusive , woman 55 120 IU/L , inclusive men , one occasion 24weeks prior screening . The patient MRI determine liver fat fraction equal high 6 % Screening Additional criterion apply , please contact investigator information The patient history chronic liver disease NASH eg , chronic acute hepatitis , autoimmune , viral ( A , B , C ) , genetic hepatitis , drug induce hepatotoxicity , Wilson 's disease , alcoholic liver disease , nonNASH active liver disease . The patient active cancer history malignant disease ( except basal cell carcinoma skin ) within 5 year prior screen history bladder cancer . The patient unstable metabolic condition ( ie , history weight loss weight gain &gt; 5 kg within 24 week prior screen ) The patient history bariatric surgery within 5 year prior screen . The patient receive mercaptopurine azathioprine previously within 1 year prior screen The patient take within 7 day prior first dose study drug ( anticipated take study ) anticholinergic drug know affect gastrointestinal ( GI ) motility , protonpump inhibitor , drug know affect gastric acidity use allopurinol . The patient receive oral antibiotic within last 4 week prior randomization ( day 1 ) . The patient receive treatment within last 30 day drug know induce inhibit endogenous hepatic drug metabolism ( eg , barbiturate , phenothiazine , cimetidine , carbamazepine ) anticoagulant therapy ( eg , heparin , warfarin , acenocoumarol ) . The patient Type 1 Diabetes Mellitus ( T1DM ) poorly control T2DM The patient body mass index ( BMI ) &lt; 25 kg/m2 . The patient history diabetic gastroparesis gastric bypass surgery within last 5 year . The patient history pancreatitis . The patient history persistent intestinal obstruction , bowel perforation , uncontrolled GI bleed abdominal abscess infection toxic megacolon inflammatory bowel disease ( IBD ) The patient history coronary angioplasty , coronary stent placement , coronary bypass surgery , unstable angina , myocardial infarction , transient ischemic event , stroke within 24weeks prior screening . The patient classify Class IIIV via New York Heart Association The patient history drug abuse ( define illicit drug use ) history excessive alcohol abuse ( define regular daily consumption 2 alcoholic drink per day woman 3 alcoholic drink per day men ) within 1 year prior screen visit . Additional criterion apply , please contact investigator information</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>